Allergan is carrying out an investment of 6.8 million euros to set up a European research center at Mougins, in the South of France. The new center, which is designed to employ about 120 researchers, is expected to start up in February of next year. It's meant to reinforce especially the company's core competence in pharmaceutical products, which will represent about 70 percent of sales this year, facilitating their introduction in Europe. Out of Allergan's total turnover of $1.56 billion in the year 2000, only 23 percent was generated in Europe.